摩卡李
Lv5
1470 积分
2021-08-24 加入
-
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study
10天前
已完结
-
Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis
25天前
已完结
-
Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China
1个月前
已完结
-
Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study
1个月前
已完结
-
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
1个月前
已完结
-
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
3个月前
已完结
-
Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study
4个月前
已完结
-
Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma
5个月前
已完结
-
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion
6个月前
已完结
-
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
10个月前
已关闭